Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Vaxneuvance by Quarter
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Vaxneuvance: -36.0% in Q2 2026, down 56.0 pts from a year earlier. That is the lowest of the 8 quarters on record here.
Where the Q2 2026 figure comes from
“|| Vaxneuvance | 202 | 148 | 350 | 230 | 229 | 459 | 226 | 140 | 825 | -35 | -36 | -24 | -26”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -36.0% | -56.0 pts | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q4 2025 | Dec 31, 2025 | -16.0% | -7.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | -7.0% | – | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 20.0% | +4.0 pts | Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | -9.0% | -35.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 16.0% | – | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 106.0% | – | Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 26.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
Cite this data
StockData. (2026). Merck Vaxneuvance (%), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaxneuvance-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.